AscellaHealth Launches Q3 2023 Specialty & Rare Pipeline Digest™: Expert Resource for FDA Approval Status of Specialty Pharmaceuticals and Cell & Gene Therapies
BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its Q3 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches and cell and gene therapies, biosimilars and generics. This complimentary, digital source of industry information supports the specialty drug market needs of all stakeholders and decision-makers including pharmaceutical manufacturers, payers and providers, with essential updates on products that may impact millions of individuals living with or affected by rare disease or complex, chronic conditions.
“As the specialty drug pipeline continues to grow year-over-year, our dedication to providing industry stakeholders with critically important and timely updates remains paramount,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “This latest edition of our Q3 2023 Specialty & Rare Pipeline Digest™ exemplifies our commitment to being at the forefront of disseminating and sharing knowledge, providing valuable insights and data to support our partners, clients, and the entire specialty pharmaceutical ecosystem.”
Dea Belazi, president & CEO, AscellaHealth, adds, “We are proud to provide The Q3 2023 Specialty & Rare Pipeline Digest™ that underscores our mission to support patients and clients with deep industry expertise to drive decision making. We applaud the relentless efforts of pharmaceutical manufacturers in developing and introducing these groundbreaking therapies. Our collaboration with all stakeholders ensures that these advancements translate into improved treatment access, patient care and outcomes.”
AscellaHealth is a single-source partner providing end-to-end, global solutions which result in the streamlined commercialization of specialty drugs, cost savings for clients and an optimal treatment journey for the rare disease / specialty population. Core Services include:
- Pre-Commercialization & Market Access
- Exclusive Distribution, Wholesale, and 3PL Services
- International Specialty Pharmacy Fulfillment including Limited Distribution Drugs
- Comprehensive HUB and Patient Support Services
- Custom Compliance and Persistency Programs
- Streamlined Prior Authorizations
- Technology-based Patient Engagement
- Integrated Copay and Financial Assistance Programs
- Real-time Rx Data and Analytics
- Specialty Pharmacy & Medical Benefit Management
Access the Q3 2023 Specialty & Rare Pipeline Digest™ here.
About AscellaHealth LLC
AscellaHealth, a global healthcare and specialty pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, including Deloitte Technology Fast 500™ and Inc. 5000, AscellaHealth’s customized, patient-centric approach is built upon proprietary technology processes for end-to-end solutions to streamline the commercialization of specialty medications and proactively address unmet client needs, optimize clinical health outcomes and improve the quality of life for this patient population. AscellaHealth brings a rare and special perspective to all stakeholders. Visit www.AscellaHealth.com.
Contacts
Media:
Nicole Dufour
CPR Communications
[email protected]
201.641.1911 x 54
Marketing:
Darcey McDermott, Chief Marketing & Communications Officer
AscellaHealth
[email protected]
877.389.9040
